{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:41:59Z","timestamp":1775738519303,"version":"3.50.1"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jns.2022.120294","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T11:56:54Z","timestamp":1653307014000},"page":"120294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?"],"prefix":"10.1016","volume":"438","author":[{"given":"Jin Jun","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Kusiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2022.120294_bb0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2110468","article-title":"Revisiting FDA approval of Aducanumab","author":"Alexander","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jns.2022.120294_bb0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and Progress in Alzheimer\u2019s disease - FDA approval of Aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0015","article-title":"Cleveland Clinic, Mount Sinai and Providence Won\u2019t Give Biogen\u2019s New Alzheimer\u2019s drug","author":"Walker","year":"2021","journal-title":"Wall Street J."},{"key":"10.1016\/j.jns.2022.120294_bb0020","series-title":"Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer\u2019s Disease. Proposed National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer\u2019s DiseasePress","author":"Baldwin","year":"2022"},{"issue":"10","key":"10.1016\/j.jns.2022.120294_bb0025","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of Aducanumab for Alzheimer Disease-The FDA\u2019s perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"3","key":"10.1016\/j.jns.2022.120294_bb0030","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ana.26181","article-title":"Aducanumab: what about the patient?","volume":"90","author":"Petersen","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1126\/science.abi6401","article-title":"Treatments for Alzheimer\u2019s disease emerge","volume":"373","author":"Selkoe","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jns.2022.120294_bb0040","series-title":"Dementia Fact sheet","author":"WHO","year":"2020"},{"key":"10.1016\/j.jns.2022.120294_bb0045","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/gps.3946","article-title":"Survival in dementia and predictors of mortality: a review","volume":"28","author":"Todd","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jns.2022.120294_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/j.1875-9114.1998.tb03880.x","article-title":"Economic considerations in Alzheimer\u2019s disease","volume":"18","author":"Meek","year":"1998","journal-title":"Pharmacotherapy"},{"issue":"Suppl. 2","key":"10.1016\/j.jns.2022.120294_bb0055","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/ajhp\/55.suppl_2.S17","article-title":"Economic considerations in the treatment and management of Alzheimer\u2019s disease","volume":"55","author":"Schumock","year":"1998","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jns.2022.120294_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"Alzheimer's disease facts and figures","volume":"17","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2022.120294_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2022.120294_bb0070","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239584","article-title":"Familial Alzheimer\u2019s disease mutations at position 22 of the amyloid beta-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system","volume":"15","author":"Tackenberg","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2022.120294_bb0080","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/ncomms6659","article-title":"The role of protein clearance mechanisms in organismal ageing and age-related diseases","volume":"5","author":"Vilchez","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jns.2022.120294_bb0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0166-2236(00)02031-2","article-title":"Alzheimer\u2019s disease-do tauists and baptists finally shake hands?","volume":"25","author":"Mudher","year":"2002","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0095","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1523\/JNEUROSCI.15-07-04896.1995","article-title":"Chronic elevation of secreted amyloid precursor protein in subcortically lesioned rats, and its exacerbation in aged rats","volume":"15","author":"Wallace","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-328X(97)00258-1","article-title":"Amyloid precursor protein potentiates the neurotrophic activity of NGF","volume":"52","author":"Wallace","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.jns.2022.120294_bb0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/1097-4547(20010301)63:5<410::AID-JNR1036>3.0.CO;2-B","article-title":"Characterization of the neurotrophic interaction between nerve growth factor and secreted alpha-amyloid precursor protein","volume":"63","author":"Luo","year":"2001","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jns.2022.120294_bb0110","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1046\/j.1471-4159.2000.0742331.x","article-title":"A monoclonal antibody to amyloid precursor protein induces neuronal apoptosis","volume":"74","author":"Rohn","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0115","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000105156","article-title":"Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches","volume":"4","author":"Van Broeck","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0120","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","article-title":"Alzheimer mechanisms and therapeutic strategies","volume":"148","author":"Huang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jns.2022.120294_bb0125","series-title":"Dual roles of amyloid-beta and secreted forms of amyloid precursor protein in culture","author":"Luo","year":"2009"},{"key":"10.1016\/j.jns.2022.120294_bb0130","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0197-4580(00)83122-X","article-title":"A truncated form of secreted amyloid precursor protein induces apoptosis of neurons in culture","volume":"21","author":"Wallace","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2022.120294_bb0135","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.neurobiolaging.2006.06.023","article-title":"Alpha- and beta-secretase activity as a function of age and beta-amyloid in down syndrome and normal brain","volume":"28","author":"Nistor","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2022.120294_bb0140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neurobiolaging.2004.08.005","article-title":"Alzheimer disease and down syndrome: factors in pathogenesis","volume":"26","author":"Lott","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2022.120294_bb0145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.jns.2022.120294_bb0150","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJM199511093331902","article-title":"Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein","volume":"333","author":"Polvikoski","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/alzrt6","article-title":"Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease","volume":"1","author":"Weller","year":"2009","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jns.2022.120294_bb0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1471-4159.2000.0740125.x","article-title":"PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons","volume":"74","author":"Rapoport","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0002-9440(10)64544-0","article-title":"Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss","volume":"157","author":"Takeuchi","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jns.2022.120294_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","article-title":"Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome","volume":"43","author":"Oddo","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2022.120294_bb0175","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(94)90131-7","article-title":"Hydrogen peroxide mediates amyloid beta protein toxicity","volume":"77","author":"Behl","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jns.2022.120294_bb0180","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0891-5849(00)00494-9","article-title":"Redox-active iron mediates amyloid-beta toxicity","volume":"30","author":"Rottkamp","year":"2001","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0185","doi-asserted-by":"crossref","first-page":"15145","DOI":"10.1074\/jbc.M600417200","article-title":"Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge","volume":"281","author":"Smith","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2022.120294_bb0190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1126\/science.2218531","article-title":"Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides","volume":"250","author":"Yankner","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.jns.2022.120294_bb0195","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/15216540601047767","article-title":"Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer\u2019s disease","volume":"58","author":"Chen","year":"2006","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jns.2022.120294_bb0200","doi-asserted-by":"crossref","first-page":"621S","DOI":"10.1093\/ajcn\/71.2.621s","article-title":"Oxidative stress and Alzheimer disease","volume":"71","author":"Christen","year":"2000","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.jns.2022.120294_bb0205","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1471-4159.2003.02059.x","article-title":"Caspase cleavage of the amyloid precursor protein modulates amyloid beta-protein toxicity","volume":"87","author":"Lu","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0210","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1471-4159.2003.02196.x","article-title":"Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression","volume":"88","author":"Liu","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0215","doi-asserted-by":"crossref","unstructured":"Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med;2:a006338.","DOI":"10.1101\/cshperspect.a006338"},{"key":"10.1016\/j.jns.2022.120294_bb0220","doi-asserted-by":"crossref","unstructured":"Freir DB, Fedriani R, Scully D, et al. Abeta oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging;32:2211\u20132218.","DOI":"10.1016\/j.neurobiolaging.2010.01.001"},{"key":"10.1016\/j.jns.2022.120294_bb0225","doi-asserted-by":"crossref","unstructured":"Reed MN, Hofmeister JJ, Jungbauer L, et al. Cognitive effects of cell-derived and synthetically derived Abeta oligomers. Neurobiol Aging;32:1784\u20131794.","DOI":"10.1016\/j.neurobiolaging.2009.11.007"},{"key":"10.1016\/j.jns.2022.120294_bb0230","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00702-002-0796-2","article-title":"Deposits of fibrillar A beta do not cause neuronal loss or ferritin expression in adult rat brain","volume":"110","author":"Bishop","year":"2003","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jns.2022.120294_bb0235","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1073\/pnas.092136199","article-title":"Tau is essential to beta -amyloid-induced neurotoxicity","volume":"99","author":"Rapoport","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2022.120294_bb0240","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease","volume":"41","author":"Gomez-Isla","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2022.120294_bb0250","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","article-title":"Can Alzheimer disease be prevented by amyloid-beta immunotherapy?","volume":"6","author":"Lemere","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0255","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","article-title":"Active Abeta immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study","volume":"3","author":"Vandenberghe","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jns.2022.120294_bb0260","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0265","first-page":"103","article-title":"Results from a phase II study to assess the clinical and immunological activity of AFFITOPE(R) AD02 in patients with early Alzheimer\u2019s disease","volume":"2","author":"Schneeberger","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.jns.2022.120294_bb0270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0275","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0896-6273(03)00810-9","article-title":"BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer\u2019s disease","volume":"41","author":"Ohno","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.jns.2022.120294_bb0280","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of Verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0285","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1750-3639.1991.tb00671.x","article-title":"Tau proteins and neurofibrillary degeneration","volume":"1","author":"Goedert","year":"1991","journal-title":"Brain Pathol."},{"key":"10.1016\/j.jns.2022.120294_bb0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jns.2022.120294_bb0295","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2741\/2097","article-title":"The role of tau phosphorylation and cleavage in neuronal cell death","volume":"12","author":"Chun","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jns.2022.120294_bb0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0305","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41374-019-0197-x","article-title":"MAPT mutations, tauopathy, and mechanisms of neurodegeneration","volume":"99","author":"Strang","year":"2019","journal-title":"Lab. Investig."},{"key":"10.1016\/j.jns.2022.120294_bb0310","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.jns.2022.120294_bb0315","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/ana.410430617","article-title":"Tau is a candidate gene for chromosome 17 frontotemporal dementia","volume":"43","author":"Poorkaj","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0320","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00005072-199906000-00011","article-title":"Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau","volume":"58","author":"Bugiani","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0325","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1073\/pnas.95.13.7737","article-title":"Mutation in the tau gene in familial multiple system tauopathy with presenile dementia","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1471-4914(01)02246-8","article-title":"Alzheimer\u2019s and Parkinson\u2019s disease\u2013overlapping or synergistic pathologies?","volume":"8","author":"Kurosinski","year":"2002","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0335","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/7454","article-title":"Tau gene mutation in familial progressive subcortical gliosis","volume":"5","author":"Goedert","year":"1999","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jns.2022.120294_bb0340","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.53.4.864","article-title":"A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration","volume":"53","author":"Yasuda","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0345","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0002-9440(10)63997-1","article-title":"Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice","volume":"158","author":"Ishihara","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jns.2022.120294_bb0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s004010051148","article-title":"Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein","volume":"99","author":"Probst","year":"2000","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jns.2022.120294_bb0355","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0002-9440(10)65533-2","article-title":"Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein","volume":"155","author":"Spittaels","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jns.2022.120294_bb0360","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00005072-198409000-00002","article-title":"Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis","volume":"43","author":"Hirano","year":"1984","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0365","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ana.410390119","article-title":"SOD1 mutation is assosiated with accumulation of neurofilaments in amyotrophic lateral scelaries","volume":"39","author":"Rouleau","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0370","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00005072-198801000-00002","article-title":"Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients","volume":"47","author":"Munoz","year":"1988","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0375","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.410440116","article-title":"Frontotemporal dementia: neuropil spheroids and presynaptic terminal degeneration","volume":"44","author":"Zhou","year":"1998","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0380","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bbadis.2004.06.014","article-title":"Transgenic animal models of tauopathies","volume":"1739","author":"Lee","year":"2005","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"10.1016\/j.jns.2022.120294_bb0385","first-page":"1403","article-title":"Davies AP and Moloney AJF","volume":"ii","author":"AJF DAaM","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2022.120294_bb0390","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/brain\/99.3.459","article-title":"Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies","volume":"99","author":"Bowen","year":"1976","journal-title":"Brain"},{"key":"10.1016\/j.jns.2022.120294_bb0395","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","article-title":"Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue","volume":"34","author":"Perry","year":"1977","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0400","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","article-title":"The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress","volume":"66","author":"Francis","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2022.120294_bb0405","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1755-5949.2010.00175.x","article-title":"Beyond the cholinergic hypothesis: do current drugs work in Alzheimer\u2019s disease?","volume":"16","author":"Martorana","year":"2010","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jns.2022.120294_bb0410","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1136\/bmj.317.7174.1698","article-title":"Brain drugs of the future","volume":"317","author":"Greenfield","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2022.120294_bb0415","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/ADR-200171","article-title":"Alzheimer\u2019s disease, inflammation, and the role of antioxidants","volume":"4","author":"Sinyor","year":"2020","journal-title":"J Alzheimers Dis Rep"},{"key":"10.1016\/j.jns.2022.120294_bb0420","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer\u2019s disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jns.2022.120294_bb0425","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000283480","article-title":"Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer\u2019s disease","volume":"7","author":"Eikelenboom","year":"2010","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0430","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1196\/annals.1332.018","article-title":"New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists","volume":"1035","author":"Greig","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0435","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","article-title":"Microglia in neurodegeneration","volume":"21","author":"Hickman","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0440","article-title":"Neuroinflammation induces neurodegeneration","volume":"1","author":"Kempuraj","year":"2016","journal-title":"Journal of Neurology, Neurosurgery and Spine"},{"key":"10.1016\/j.jns.2022.120294_bb0445","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jns.2022.120294_bb0450","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/glia.10154","article-title":"Microglia as neuroprotective, immunocompetent cells of the CNS","volume":"40","author":"Streit","year":"2002","journal-title":"Glia"},{"key":"10.1016\/j.jns.2022.120294_bb0455","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer\u2019s disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2022.120294_bb0460","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nm838","article-title":"Adult mouse astrocytes degrade amyloid-\u03b2 in vitro and in situ","volume":"9","author":"Wyss-Coray","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0465","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.brainresrev.2004.07.021","article-title":"Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases","volume":"48","author":"Cartier","year":"2005","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.jns.2022.120294_bb0470","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/j.jns.2022.120294_bb0480","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fphar.2019.01008","article-title":"Neuroinflammation as a common feature of neurodegenerative disorders","volume":"10","author":"Guzman-Martinez","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jns.2022.120294_bb0485","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ijms19040956","article-title":"Neuroimmune tau mechanisms: their role in the progression of neuronal degeneration","volume":"19","author":"Cort\u00e9s","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0490","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1749-6632.2008.03972.x","article-title":"The role of neuroimmunomodulation in Alzheimer\u2019s disease","volume":"1153","author":"Maccioni","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0495","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0500","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00702-017-1795-7","article-title":"Differential contribution of microglia and monocytes in neurodegenerative diseases","volume":"125","author":"Baufeld","year":"2018","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jns.2022.120294_bb0505","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","article-title":"Reactive astrocytes: production, function, and therapeutic potential","volume":"46","author":"Liddelow","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jns.2022.120294_bb0510","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1007\/s00018-019-03111-7","article-title":"Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms","volume":"76","author":"Oksanen","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0515","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3233\/JAD-161020","article-title":"Rhamnolipids, microbial virulence factors, in Alzheimer\u2019s disease","volume":"59","author":"Andreadou","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0520","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.25895","article-title":"Peptidoglycan recognition protein genes and risk of Parkinson\u2019s disease","volume":"29","author":"Goldman","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2022.120294_bb0525","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1073\/pnas.1711233114","article-title":"Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice","volume":"114","author":"Berer","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0530","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: an evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0535","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev.pathmechdis.2.010506.092044","article-title":"The aging brain","volume":"3","author":"Yankner","year":"2008","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"3","key":"10.1016\/j.jns.2022.120294_bb0540","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease. Alzheimer\u2019s Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0545","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"Jama"},{"key":"10.1016\/j.jns.2022.120294_bb0550","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1474-4422(07)70293-4","article-title":"Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial","volume":"7","author":"Group AC","year":"2008","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/j.jns.2022.120294_bb0555","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0560","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","article-title":"A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment","volume":"30","author":"Thal","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jns.2022.120294_bb0565","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.2008.65.7.nct70006","article-title":"Cognitive function over time in the Alzheimer\u2019s disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib","volume":"65","author":"Group AR","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0570","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clin. Exp. Res."},{"issue":"8","key":"10.1016\/j.jns.2022.120294_bb0575","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1212\/WNL.43.8.1609","article-title":"Clinical trial of indomethacin in Alzheimer\u2019s disease","volume":"43","author":"Rogers","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0580","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/glia.20268","article-title":"Inhibitory effect of minocycline on amyloid \u03b2 fibril formation and human microglial activation","volume":"53","author":"Familian","year":"2006","journal-title":"Glia"},{"key":"10.1016\/j.jns.2022.120294_bb0585","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pnpbp.2017.03.010","article-title":"Minocycline reduces inflammatory parameters in the brain structures and serum and reverses memory impairment caused by the administration of amyloid \u03b2 (1-42) in mice","volume":"77","author":"Garcez","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2022.120294_bb0590","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","article-title":"Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0595","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/nbdi.2002.0487","article-title":"Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis","volume":"10","author":"Kriz","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0600","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial","volume":"6","author":"Gordon","year":"2007","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0605","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tips.2009.01.002","article-title":"The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: implications for translational research","volume":"30","author":"Choi","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jns.2022.120294_bb0610","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0615","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0620","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1474-4422(18)30450-2","article-title":"Implications of sleep disturbance and inflammation for Alzheimer\u2019s disease dementia","volume":"18","author":"Irwin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0625","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3233\/JAD-2010-1240","article-title":"Cigarette smoking is a risk factor for Alzheimer\u2019s disease: an analysis controlling for tobacco industry affiliation","volume":"19","author":"Cataldo","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0630","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/472751","article-title":"Air pollution, oxidative stress, and Alzheimer\u2019s disease","volume":"2012","author":"Moulton","year":"2012","journal-title":"J. Environ. Public Health"},{"key":"10.1016\/j.jns.2022.120294_bb0635","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-publhealth-040218-044058","article-title":"Ambient air pollution, noise, and late-life cognitive decline and dementia risk","volume":"40","author":"Paul","year":"2019","journal-title":"Annu. Rev. Public Health"},{"key":"10.1016\/j.jns.2022.120294_bb0640","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/156720507780362245","article-title":"Role of the blood-brain barrier in the pathogenesis of Alzheimer\u2019s disease","volume":"4","author":"Deane","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jns.2022.120294_bb0645","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fnagi.2014.00121","article-title":"Interactions of metals and apolipoprotein E in Alzheimer\u2019s disease","volume":"6","author":"Xu","year":"2014","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0650","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1212\/01.wnl.0000192102.41141.9e","article-title":"Apolipoprotein E and Alzheimer disease","volume":"66","author":"Huang","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0655","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1073\/pnas.0600549103","article-title":"Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer\u2019s disease","volume":"103","author":"Mahley","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jns.2022.120294_bb0660","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresrev.2008.07.007","article-title":"New insights into brain BDNF function in normal aging and Alzheimer disease","volume":"59","author":"Tapia-Arancibia","year":"2008","journal-title":"Brain Res. Rev."},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2022.120294_bb0665","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1601-183X.2007.00378.x","article-title":"Neurotrophic factors in Alzheimer\u2019s disease: role of axonal transport","volume":"7","author":"Schindowski","year":"2008","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.jns.2022.120294_bb0670","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.neurobiolaging.2009.08.007","article-title":"Alzheimer\u2019s disease as homeostatic responses to age-related myelin breakdown","volume":"32","author":"Bartzokis","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2022.120294_bb0675","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00207454.2015.1025778","article-title":"Oligodendrocytes and Alzheimer\u2019s disease","volume":"126","author":"Cai","year":"2016","journal-title":"Int J Neurosci"},{"issue":"Suppl. 3","key":"10.1016\/j.jns.2022.120294_bb0680","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/PL00014170","article-title":"Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer\u2019s and other dementing processes","volume":"249","author":"Reisberg","year":"1999","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0685","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-2094-8-90","article-title":"Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria","volume":"8","author":"Miklossy","year":"2011","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jns.2022.120294_bb0690","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3233\/JAD-160388","article-title":"Alzheimer\u2019s disease: assessing the role of spirochetes, biofilms, the immune system, and amyloid-beta with regard to potential treatment and prevention","volume":"53","author":"Allen","year":"2016","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0695","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jalz.2007.08.004","article-title":"Inflammation and Alzheimer\u2019s disease: possible role of periodontal diseases","volume":"4","author":"Kamer","year":"2008","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2022.120294_bb0700","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-2008-13408","article-title":"Alzheimer\u2019s disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis","volume":"13","author":"Kamer","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0705","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nrmicro2876","article-title":"The interplay between the intestinal microbiota and the brain","volume":"10","author":"Collins","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jns.2022.120294_bb0710","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1567205012666150204121719","article-title":"Role of environmental contaminants in the etiology of Alzheimer\u2019s disease: a review","volume":"12","author":"Yegambaram","year":"2015","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jns.2022.120294_bb0720","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/08977194.2020.1864347","article-title":"A narrative review of brain-derived neurotrophic factor (BDNF) on cognitive performance in Alzheimer\u2019s disease","volume":"38","author":"Ismail","year":"2020","journal-title":"Growth Factors"},{"key":"10.1016\/j.jns.2022.120294_bb0725","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"Journal of central nervous system disease"},{"key":"10.1016\/j.jns.2022.120294_bb0730","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer\u2019s disease drug development pipeline: 2019","volume":"5","author":"Cummingsa","year":"2019","journal-title":"Alzheimer Dement"},{"key":"10.1016\/j.jns.2022.120294_bb0735","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2009.03.047","article-title":"Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells","volume":"610","author":"Yang","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jns.2022.120294_bb0740","first-page":"234","article-title":"Selegiline in the treatment of Alzheimer\u2019s disease: a long-term randomized placebo-controlled trial. Czech and Slovak senile dementia of Alzheimer type study group","volume":"24","author":"Filip","year":"1999","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0745","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000073981","article-title":"Association between statin use and Alzheimer\u2019s disease","volume":"23","author":"Zamrini","year":"2004","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jns.2022.120294_bb0750","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1471-4159.2004.02521.x","article-title":"Atorvastatin-induced activation of Alzheimer\u2019s alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding","volume":"90","author":"Parvathy","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0755","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer\u2019s disease: a 3-month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jns.2022.120294_bb0760","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1471-4159.2008.05396.x","article-title":"Etazolate, a neuroprotective drug linking GABA(a) receptor pharmacology to amyloid precursor protein processing","volume":"106","author":"Marcade","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0765","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1523\/JNEUROSCI.1521-05.2005","article-title":"Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice","volume":"25","author":"Rezai-Zadeh","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0770","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1074\/jbc.M600617200","article-title":"ADAM10 activation is required for green tea (\u2212)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein","volume":"281","author":"Obregon","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2022.120294_bb0775","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0780","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-180759","article-title":"A randomized, double-blind, placebo-controlled, phase II study assessing safety, tolerability, and efficacy of Bryostatin in the treatment of moderately severe to severe Alzheimer\u2019s disease","volume":"67","author":"Farlow","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jns.2022.120294_bb0785","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","article-title":"Mice deficient in BACE1, the Alzheimer\u2019s beta-secretase, have normal phenotype and abolished beta-amyloid generation","volume":"4","author":"Luo","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0790","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/hmg\/10.12.1317","article-title":"BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer\u2019s disease therapeutics","volume":"10","author":"Roberds","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jns.2022.120294_bb0795","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1460-9568.2005.04551.x","article-title":"Temporal memory deficits in Alzheimer\u2019s mouse models: rescue by genetic deletion of BACE1","volume":"23","author":"Ohno","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0800","doi-asserted-by":"crossref","first-page":"9100","DOI":"10.1074\/jbc.M109.060061","article-title":"AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism","volume":"285","author":"Vingtdeux","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2022.120294_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173412","article-title":"Neuroprotective role of polyphenols against oxidative stress-mediated neurodegeneration","volume":"886","author":"Uddin","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jns.2022.120294_bb0810","doi-asserted-by":"crossref","first-page":"37377","DOI":"10.1074\/jbc.M508246200","article-title":"Resveratrol promotes clearance of Alzheimer\u2019s disease amyloid-beta peptides","volume":"280","author":"Marambaud","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jns.2022.120294_bb0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029102","article-title":"Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation","volume":"6","author":"Huang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jns.2022.120294_bb0820","first-page":"219","article-title":"Clinical benefits of Tramiprosate in Alzheimer\u2019s disease are associated with higher number of APOE4 alleles: the \u201cAPOE4 gene-dose effect\u201d","volume":"3","author":"Abushakra","year":"2016","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.jns.2022.120294_bb0825","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.trci.2018.09.009","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer\u2019s disease: a pilot study","volume":"4","author":"Zhu","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jns.2022.120294_bb0830","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/alzrt146","article-title":"Oral curcumin for Alzheimer\u2019s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study","volume":"4","author":"Ringman","year":"2012","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jns.2022.120294_bb0835","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0840","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jns.2022.120294_bb0845","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/35050110","article-title":"A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease","volume":"408","author":"Janus","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jns.2022.120294_bb0850","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jns.2022.120294_bb0855","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120294_bb0860","first-page":"319","article-title":"Advances in the development of vaccines for Alzheimer\u2019s disease","volume":"15","author":"Lambracht-Washington","year":"2013","journal-title":"Discov. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0865","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1523\/JNEUROSCI.0293-11.2011","article-title":"The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects","volume":"31","author":"Wiessner","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0870","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2022.120294_bb0875","first-page":"5","article-title":"Results of the first-in-man study with the active A\u03b2 Immunotherapy CAD106 in Alzheimer patients","author":"Winblad","year":"2009","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2022.120294_bb0880","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/jama.2009.1547","article-title":"DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model","volume":"302","author":"Lambracht-Washington","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2022.120294_bb0885","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1016\/j.vaccine.2010.05.054","article-title":"Analysis of three plasmid systems for use in DNA a beta 42 immunization as therapy for Alzheimer\u2019s disease","volume":"28","author":"Qu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jns.2022.120294_bb0890","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13195-018-0441-4","article-title":"Active full-length DNA Abeta42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology","volume":"10","author":"Rosenberg","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.jns.2022.120294_bb0895","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jns.2022.120294_bb0900","series-title":"FDA grants accelerated approval for Alzheimer\u2019s drug","author":"Food, Administration D","year":"2021"},{"key":"10.1016\/j.jns.2022.120294_bb0905","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2022.120294_bb0910","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jns.2022.120294_bb0915","first-page":"4","article-title":"EMERGE and ENGAGE topline results: two phase 3 studies to evaluate aducanumab in patients with early Alzheimer\u2019s disease","author":"Budd-Haeberlein","year":"2019","journal-title":"Clinical Trials on Alzheimer\u2019s Disease Conference"},{"key":"10.1016\/j.jns.2022.120294_bb0920","article-title":"Aducanumab for Alzheimer\u2019s disease: effectiveness and value; draft evidence report","volume":"5","author":"Lin","year":"2021","journal-title":"Institute for Clinical and Economic Review"},{"key":"10.1016\/j.jns.2022.120294_bb0925","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jns.2022.120294_bb0930","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7326\/M21-2603","article-title":"The problem of Aducanumab for the treatment of Alzheimer disease","volume":"174","author":"Alexander","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0935","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0169-328X(97)00259-3","article-title":"Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity","volume":"52","author":"Wallace","year":"1997","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.jns.2022.120294_bb0940","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1046\/j.1471-4159.1994.63020781.x","article-title":"Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury","volume":"63","author":"Smith-Swintosky","year":"1994","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jns.2022.120294_bb0945","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/(SICI)1097-4547(19990301)55:5<629::AID-JNR10>3.0.CO;2-Y","article-title":"Death of PC12 cells and hippocampal neurons induced by adenoviral-mediated FAD human amyloid precursor protein gene expression","volume":"55","author":"Luo","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jns.2022.120294_bb0950","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1126\/science.2928783","article-title":"Amyloid beta protein enhances the survival of hippocampal neurons in vitro","volume":"243","author":"Whitson","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jns.2022.120294_bb0955","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1523\/JNEUROSCI.23-13-05531.2003","article-title":"The production of amyloid beta peptide is a critical requirement for the viability of central neurons","volume":"23","author":"Plant","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0960","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1523\/JNEUROSCI.1736-09.2009","article-title":"Beta-amyloid monomers are neuroprotective","volume":"29","author":"Giuffrida","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0965","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1523\/JNEUROSCI.0974-04.2004","article-title":"Neurogenic effect of beta-amyloid peptide in the development of neural stem cells","volume":"24","author":"Lopez-Toledano","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jns.2022.120294_bb0970","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.pneurobio.2006.03.004","article-title":"Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference","volume":"78","author":"Rao","year":"2006","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jns.2022.120294_bb0975","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.freeradbiomed.2012.09.036","article-title":"Antioxidant role of amyloid beta protein in cell-free and biological systems: implication for the pathogenesis of Alzheimer disease","volume":"56","author":"Sinha","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jns.2022.120294_bb0980","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/jnr.10661","article-title":"Human Abeta1-42 reduces iron-induced toxicity in rat cerebral cortex","volume":"73","author":"Bishop","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.jns.2022.120294_bb0985","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0197-4580(01)00342-6","article-title":"Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer\u2019s disease","volume":"23","author":"Robinson","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jns.2022.120294_bb0990","author":"Whitehouse"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22001563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22001563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:59:02Z","timestamp":1758383942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22001563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":197,"alternative-id":["S0022510X22001563"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120294","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120294"}}